Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit

University of Manitoba

Overview

This proposed pharmacokinetic study will test the hypothesis that in critically ill patients with respiratory failure requiring mechanical ventilation such as might be anticipated to be needed to treat patients with severe influenza pneumonia, oseltamivir administered enterally via nasogastric tube, with and without concomitant food or alimentation, will have similar oral bioavailability to that observed in ambulatory adults ill with influenza in whom oseltamivir therapy 75 mg BID is efficacious and well tolerated. Additionally, this experiment will test the hypothesis that increasing the dose (150 mg), with and without concomitant enteral feeding, will show a proportionate increase in bioavailability. Relative oral bioavailability will be assessed from plasma concentration vs. time over 12 hrs and urinary recovery of drug from 0 to 48 hrs after administration.

Not required

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Conditions

Influenza A Virus Infection Influenza B Virus Infection

Interventions

Oseltamivir 75 mgDRUG

The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients admitted to the Intensive Care Unit requiring mechanical ventilation due to respiratory failure * must be within the ages of 18-75 yrs Exclusion Criteria: * patients unable to have enteral feeding * intolerance to oseltamivir * pregnancy * gastrointestinal or malabsorptive disease * intestinal bypass surgery * diarrhea (\>2 loose bowel movements per day) * receipt of prokinetic medications (metoclopramide, domperidone, erythromycin) * severe liver disease (hepatocellular enzymes \> 3 times the upper limit of normal) * renal failure (Cockroft-Gault Creatinine Clearance \< 30 ml/min, Dialysis dependant) * cystic fibrosis * intoxication or drug overdose

Locations (1)

Health Sciences Centre

Winnipeg, Manitoba, Canada

Outcomes

Primary Outcomes

Oseltamivir administered enterally via nasogastric tube, with and without concomitant food or alimentation, will have similar oral bioavailability to that observed in ambulatory adults .

Time frame: 13 months

Secondary Outcomes

Test the hypothesis that increasing the dose (150 mg), with and without concomitant enteral feeding, will show a proportionate increase in bioavailability.

Time frame: 13 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.